Guglielmo Ferrari

Dr. Guglielmo Ferrari

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 March 2022 in Microorganisms
Verified
Journal Article
Open access
PDF file
FGFederica Giardina
Federica Giardina
APAntonio Piralla
Antonio Piralla
GFGuglielmo Ferrari
Guglielmo Ferrari
FZFederica Zavaglio
Federica Zavaglio
ICIrene Cassaniti
Irene Cassaniti
Fausto BaldantiFausto Baldanti
Fausto Baldanti
Rhinovirus is one of the most common respiratory viruses, causing both upper and lower respiratory tract infections. It affects mainly children and could cause prolonged infections, especially in immunocompromised patients. Here we report our data on a 15-month surveillance of Rhinovirus seasonality and circulation in Lombardy Region, Italy. All rhinovirus/enterovirus-positive samples were amplified with RT-PCR for the VP4-VP2 region to assign the correct genotype. The median age of RV/EV-positive patients is 9 years, with a range of 0–96. RV-A and RV-C were detected in the majority of cases, while RV-B accounted for less than 10% of cases. An enterovirus species was detected in 6.45% of the cases. A total of 7% of the patients included in this study had a prolonged infection with a median duration of 62 days. All these patients were immunocompromised and most of them were pediatric with an RV-A infection. Two outbreaks were identified, mainly in the neonatal intensive care unit (NICU) and Oncohematology Department, caused by RV A89 and C43, respectively. Nearly 4.5% of the patients were admitted to the ICU requiring mechanical ventilation; all of which had preexisting comorbidities.

15 December 2022 in Clinical and Experimental Medicine
Verified
Journal Article
Open access
PDF file
APALESSANDRA PIERANGELI
ALESSANDRA PIERANGELI
APAntonio Piralla
Antonio Piralla
SRSara Colonia Uceda Renteria
Sara Colonia Uceda Renteria
GGGiovanni Giacomel
Giovanni Giacomel
GLGiovanna Lunghi
Giovanna Lunghi
Fausto BaldantiFausto Baldanti
Fausto Baldanti
Respiratory syncytial virus (RSV) and human metapneumovirus (HMPV) cause a high burden of disease, particularly in children and the elderly. With the aim to add knowledge on RSV and HMPV infections in Italy, a prospective, multicenter study was conducted by eight centers of the Working Group on Respiratory Virus Infections (GLIViRe), from December 2018–April 2019. Weekly distribution and patients’ demographic and clinical data were compared in 1300 RSV and 222 HMPV-positive cases. Phylogenetic analysis of the G-glycoprotein coding region was performed to characterize circulating strains. RSV positivity ranged from 6.4% in outpatients of all ages to 31.7% in hospitalized children; HMPV positivity was 4–1.2% with no age-association. RSV season peaked in February and ended in mid-April: HMPV circulation was higher when RSV decreased in early spring. RSV was more frequent in infants, whereas HMPV infected comparatively more elderly adults; despite, their clinical course was similar. RSV-B cases were two-thirds of the total and had similar clinical severity compared to RSV-A. Phylogenetic analysis showed the circulation of RSV-A ON1 variants and the predominance of RSV-B genotype BA10. HMPV genotype A2c was the prevalent one and presented insertions of different lengths in G. This first multicenter Italian report on seasonality, age-specific distribution, and clinical presentation of RSV and HMPV demonstrated their substantial disease burden in young patients but also in the elderly. These data may provide the basis for a national respiratory virus surveillance network.

7 March 2024 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
LPLaura Pellegrinelli
Laura Pellegrinelli
CGCristina Galli
Cristina Galli
FGFederica Giardina
Federica Giardina
GFGuglielmo Ferrari
Guglielmo Ferrari
SRSara Colonia Uceda Renteria
Sara Colonia Uceda Renteria
FBFausto Baldanti
Fausto Baldanti
Following the alert of echovirus 11 (E-11) infection in neonates in EU/EEA Member States, we conducted an investigation of E-11 circulation by gathering data from community and hospital surveillance of enterovirus (EV) in northern Italy from 01 August 2021 to 30 June 2023. Virological results of EVs were obtained from the regional sentinel surveillance database for influenza-like illness (ILI) in outpatients, and from the laboratory database of ten hospitals for inpatients with either respiratory or neurological symptoms. Molecular characterization of EVs was performed by sequence analysis of the VP1 gene. In our ILI series, the rate of EV-positive specimens showed an upward trend from the end of May 2023, culminating at the end of June, coinciding with an increase in EV-positive hospital cases. The E-11 identified belonged to the D5 genogroup and the majority (83%) were closely associated with the novel E-11 variant, first identified in severe neonatal infections in France since 2022. E-11 was identified sporadically in community cases until February 2023, when it was also found in hospitalized cases with a range of clinical manifestations. All E-11 cases were children, with 14 out of 24 cases identified through hospital surveillance. Of these cases, 60% were neonates, and 71% had severe clinical manifestations. Baseline epidemiological data collected since 2021 through EV laboratory-based surveillance have rapidly tracked the E-11 variant since November 2022, alongside its transmission during the late spring of 2023.

24 July 2025 in Journal of Travel Medicine
Verified
Journal Article
Closed access
GRGreta Romano
Greta Romano
APAlessandro Pavesi
Alessandro Pavesi
AFAlessandro Ferrari
Alessandro Ferrari
GFGuglielmo Ferrari
Guglielmo Ferrari
APAntonio Piralla
Antonio Piralla
FBFausto Baldanti
Fausto Baldanti
Two imported Chikungunya cases were detected in northern Italy in 2025, linked to the strains circulating in Réunion Island. Genomic analysis revealed mutations enhancing Aedes albopictus transmission. These findings raise concern for local spread and highlight the importance of genomic surveillance, vector control and preparedness against emerging arboviral threats in Europe.

29 April 2022 in Vaccines
Verified
Journal Article
Open access
PDF file
JSjosè camilla sammartino
josè camilla sammartino
ICIrene Cassaniti
Irene Cassaniti
AFAlessandro Ferrari
Alessandro Ferrari
FGFederica Giardina
Federica Giardina
GFGuglielmo Ferrari
Guglielmo Ferrari
EPElena Percivalle
Elena Percivalle
SARS-CoV-2 still represents a global health burden, causing more than six million deaths worldwide. Moreover, the emergence of new variants has posed new issues in terms of vaccine efficacy and immunogenicity. In this study, we aimed to evaluate the neutralizing antibody response against SARS-CoV-2 variants in different cohorts of vaccinated and unvaccinated subjects. Four-fold diluted sera from SARS-CoV-2 naïve and recovered subjects vaccinated with two or three doses of the BNT162b2 vaccine were challenged against 14 SARS-CoV-2 variants, and the SARS-CoV-2 neutralizing antibody titer was measured. Results were compared with those obtained from unvaccinated COVID-19 recovered patients. Overall, a better SARS-CoV-2 NT Abs response was observed in recovered vaccinated subjects after three doses of the vaccine when compared to unvaccinated patients and vaccinated subjects with only two doses. Additionally, the lowest level of response was observed against the Omicron variant. In conclusion, third doses of BNT162b2 vaccine seems to elicit a sustained response against the large majority of variants.

15 July 2025 in The Journal of Infectious Diseases
Verified
Journal Article
Open access
AMAlessandro Mancon
Alessandro Mancon
LPLaura Pellegrinelli
Laura Pellegrinelli
GRGreta Romano
Greta Romano
EVElisa Vian
Elisa Vian
VBValeria Biscaro
Valeria Biscaro
AGAMCLI-GLIViRe Working Group
AMCLI-GLIViRe Working Group
Background: Human metapneumovirus (hMPV) infections have a significant impact on public health. However, the extent of this burden in Italy remains poorly defined due to a lack of comprehensive data. The aim of this cross-sectional multicenter study was to understand the epidemiology of hMPV in Italy, particularly in older adults. Methods: We analyzed laboratory data from molecular respiratory viral diagnostic tests conducted at 17 centers across Italy from September 2022 to August 2024. Respiratory viruses were tested from outpatients for epidemiologic surveillance and from patients presenting to tertiary hospitals for diagnostic purpose. G gene sequencing was performed on a limited number of circulating strains. Results: Data from 96 460 tests yielded an overall hMPV positivity rate of 3.4%; the hMPV positivity rate was 2.6% in adults aged 50 years and older, a third of whom were aged >80 years. In north-west Italy, hMPV was detected more frequently in outpatients than in hospitalized patients. The temporal distribution of cases showed seasonal peaks in February 2023 and April 2024, which exhibited some geographic variation but overlapped in the general population and in the elderly. Phylogenetic analysis suggested an even distribution of hMPV-A and -B, with a predominance of clades A2c with a 111-nucleotide duplication and B2b, and the possible extinction of previously circulating clades A2c with a 180-nucleotide duplication and B2a. Conclusions: hMPV was shown to be a relevant respiratory pathogen in older adults, who could be more likely to have severe outcomes. These findings may inform hMPV surveillance and the development of prevention strategies.